Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)

• Published in: BMC infectious diseases Vol. 23; no. 1; pp. 258 - 5
• Main Authors: Tuan, Jessica J., Sharma, Manas, Kayani, Jehanzeb, Davis, Matthew W., McManus, Dayna, Topal, Jeffrey E., Ogbuagu, Onyema
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.04.2023; BioMed Central; BMC
• Subjects: Adult; Allergic reactions; Antibodies, Monoclonal, Humanized - adverse effects; BNT162 Vaccine; Body mass index; Body size; Care and treatment; Clinical outcomes; Complications and side effects; Coronaviruses; COVID-19; COVID-19 vaccines; Demographics; Diabetes; Diabetes mellitus; Diagnosis; Disease control; Dosage and administration; Electronic health records; Electronic medical records; Emergency medical care; Emergency medical services; Female; Fetuses; Health aspects; Health services; HIV; Hospitalization; Human immunodeficiency virus; Humans; Hypersensitivity; Immunization; Infant, Newborn; Infectious diseases; Medical records; Medical screening; Monoclonal antibodies; mRNA; Neonates; Obstetrics; Omicron; Patients; Preeclampsia; Pregnancy; Pregnancy complications; Pregnancy Complications, Infectious - drug therapy; Pregnancy, Complications of; Pregnant Women; Premature labor; Public health; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sickle cell anemia; Sickle cell disease; Sotrovimab; Vaccination; Womens health; United States; United States > US; Connecticut; COVID-19; Pregnancy; Monoclonal antibodies; Sotrovimab; Omicron

Sotrovimab, a monoclonal antibody with efficacy against SARS-CoV-2 including certain Omicron variants, has been used in treatment of mild-moderate COVID-19. Limited data exists regarding its use in pregnant women. Electronic medical record review of pregnant COVID-19 patients treated with sotrovimab...